Teva Pharmaceutical Industries (TEVA) Goodwill & Intangibles (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Goodwill & Intangibles for 18 consecutive years, with $19.4 billion the latest figure, recorded in Q1 2026.

• Quarterly Goodwill & Intangibles fell 1.19% year-over-year to $19.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 billion (down 1.19% YoY) and the FY2025 annual result came in at $19.8 billion, down 3.12% from the prior year.
• Goodwill & Intangibles slipped to $19.4 billion in Q1 2026 per TEVA's latest filing, from $19.8 billion in the prior quarter.
• Over the last five years, Goodwill & Intangibles for TEVA reached as high as $27.1 billion in Q1 2022 and fell as low as $7.2 billion in Q2 2022.
• A 5-year average of $21.0 billion and a median of $21.3 billion in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles sank 74.85% — and 2023, when it soared 218.37%.
• Year by year, Goodwill & Intangibles stood at $23.4 billion in 2022, then dropped by 3.77% to $22.6 billion in 2023, then fell by 9.51% to $20.4 billion in 2024, then slipped by 3.12% to $19.8 billion in 2025, then declined by 1.77% to $19.4 billion in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $19.4 billion, $19.8 billion, and $19.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.